Bing

SEARCH HISTORY

... so enamored with Celgene CELG-2.96 % ’s proposed acquisition of Receptos, RCPT-0.12 % they are apparently willing to look past troubling new earnings guidance. Celgene’s stock jumped 7% on Wednesday in response to the company’s …
Wall Street Journal · 7/15/2015
Shares of Celgene Corp (CELG.O) rose as much as 9.7 percent on Monday after a late-stage clinical trial showed its drug Abraxane improved survival in patients with pancreatic cancer. Celgene, which unexpectedly reported the results late on Friday ...
Reuters · ByToni Clarke · 11/12/2012
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that its stockholders approved a two-for-one stock split and an increase from 575 million to 1,150 million in the number of authorized shares of the Company's …
Business Wire · 6/19/2014
Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced is that the run up in shares has lowered its average daily volume. The …
24/7 Wall ST · 6/19/2014
Celgene Corporation (NASDAQ: CELG) gained 9.5% to $134.50 after the company announced its plans to acquire Receptos for $7.2 billion and lifted its earnings forecast for 2015. Share volume was 10.2 million, overwhelming an all-day average of 4.4 million
BayStreet · 7/15/2015
Mid cap cancer stock Juno Therapeutics Inc (NASDAQ ... BLCM) along with large cap Celgene Corporation (NASDAQ: CELG). I should mention that we have just added Juno Therapeutics to our SmallCap Network Elite Opportunity (SCN EO) portfolio as …
Smallcap Network · ByJohn Udovich · 6/26/2015
Celgene Corporation (NASDAQ:CELG), Kinder Morgan Inc (NYSE:KMI), Chipotle Mexican Grill, Inc. (NYSE:CMG) are among the top stock picks of Jim Cramer over the last 30 days. Cramer has mentioned each of these stocks at least 4 times during the …
stockwisedaily.com · 11/24/2014
The biotechnology company Celgene said yesterday that it would pay $2.9 billion in cash and stock to acquire Pharmion, strengthening Celgene’s cancer drug portfolio and its distribution in Europe. It is one of the first big acquisitions for Celgene ...
New York Times · ByAndrew Pollack · 11/19/2007
Biotechnology giant Celgene Corp. said Wednesday that a drug it was testing for a particular type of arthritis failed to reach its goals, but the news seemed to have little effect on the company’s stock price. Instead of falling, Celgene /quotes/zigman ...
Market Watch Commentary · ByRuss Britt · 7/9/2014
A key contributor to Celgene's outsize stock performance this year has been investor read-through from management's confidence on hitting near-and long-term financial metrics. Investors should not be surprised to have management be similarly bullish on ...
istock Analyst · 1/8/2014

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia